News & insights

Check out our latest updates

Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes-002 project

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims...

Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease

Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI).  The landmark initiative will use Cambridge Cognition’s...

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced...
Load more
Scroll to Top